Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2008-04-15
2008-04-15
Dodson, Shelley A. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C424S059000, C424S060000, C424S400000, C424S703000, C514S859000, C514S861000, C514S863000, C514S864000
Reexamination Certificate
active
07357938
ABSTRACT:
A method for treating rosacea in a patient comprising administering to a patient suffering from rosacea a first topical composition comprising at least one sulfacetamide or a derivative thereof and at least one sunscreen, wherein the administration of said first composition provides a more effective treatment of said rosacea in comparison to treatment of rosacea achieved by administration of a second topical composition comprising metronidazole.
REFERENCES:
patent: 4847071 (1989-07-01), Bissett et al.
patent: 4895727 (1990-01-01), Allen
patent: 5017366 (1991-05-01), Stiefel et al.
patent: 5567420 (1996-10-01), McEleney et al.
patent: 6482839 (2002-11-01), Thornfeldt
patent: 6514489 (2003-02-01), Shacknai et al.
patent: 7022332 (2006-04-01), Stiefel
patent: 2003/0118526 (2003-06-01), Stiefel
patent: 2161737 (1997-05-01), None
patent: 0692254 (1996-01-01), None
patent: 03/006005 (2003-01-01), None
Bonnar, E. et al. The Demodex mite population in rosacea,Journal of the American Academy of Dermatology, Mar. 1993, pp. 443-448.
Wilkin, J. K. “Flushing Disorders”,Principles and Practice of Dermatology, Sams and Lynch Editors, 1990, pp. 495-500.
Kelly, A. P. “Rosacea”,Principles and Practice of Dermatology, Sams and Lynch Editors, 1990, pp. 789-791.
Food and Drug Administration, “Sunscreen Drug Products for Over-The-Counter Human Use”, Final Monograph, Federal Register, May 21, 1999, vol. 64, No. 98, pp. 1-54.
Draelos, Z. K., “Sunscreens”,Cosmetics In Dermatology, Churchill Livingston Inc. (1990), pp. 164-166.
Nichols, K. et al., “Effective Sunscreen Ingredients and Cutaneous Irritation in Patients with Rosacea”,Cutis, vol. 61, Jun. 1998, pp. 344-346.
“Sunscreen Drug Products for Over-the Counter Human Use; Amendment to the Tentative Final Monograph, Enforcement Policy”,63 Fed. Reg. 56584(Oct. 22, 1998).
The United States Pharmacopeia, Twentieth Revision, Official from Jul. 1, 1980, United States Pharmacopeial Convention, Inc., p. 744.
Physicians' Desk Reference Sulfacet R® lotion Edition 31, (1977), pp. 755-756.
“The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study”, Sauder et al.,J. Derm. Treat., (1997) 8, pp. 79-85.
Lebwohl, et al., “The Comparative Efficacy of Sodium Sulfacetamide 10%/Sulfur 5% (Sulfacet-R®) Lotion and Metronidazole 0.75% (MetroGel®) in the Treatment of Rosacea”,J. of Geriatric Dermatology, 3(5): pp. 183-185 (1995).
Zoe Diana Draelos, MD, PA; “Cosmetics,” http://www.emedicine.com/derm/topic502.htm, printed Aug. 8, 2006.
Cosmetic Ingredient Dictionary, “Search Results For: Silica,” http://www.cosmeticcop.com/learn/disctionary.asp?keys=silica&pos=1&type=FIND, printed Aug. 8, 2006.
21 C.F.R. § 352.10 (Apr. 1, 2006 edition), “Subpart B-Active Ingredients,”http://www.access.gpo.gov
ara/cfr/waisidx—06/21cfr352—06.html, printed Aug. 8, 2006.
21 C.F.R. § 352.76 (Apr. 1, 2006), “Determination if a product is water resistant or etc.,” http://www.access.gpo.gov
ara/cfr/waisidx—06/21cfr352—06.html, printed Aug. 8, 2006.
Bradley Pharmaceuticals, Inc., “Sulfacet R labeling,” http://www.bradphram.com/intl/dermik.html, printed Aug. 10, 2006.
Bradley Pharmaceuticals, Inc., “Sulfacet R labeling,” http://www.bradphram.com/intl/pdf/SULF2—Ins.pdfhtml, printed Aug. 10, 2006.
Lebwohl, et al., “The Comparative Efficacy of Sodium Sulfacetamide 10%/Sulfur 5% (Sulfacet-R®) Lotion and Metronidazole 0.75% (MetroGel®) in the Treatment of Rosacea”,J. of Geriatric Dermatology, 3:191-195 (1995).
Stanislaw Bucchner, MD., “Rosacea: An Update,” Dermatology, 210, pp. 100-108 (2005).
Michelle T. Pelle et al., “Continuing Medical Education: Rosacea: II. Therapy,” J. Am. Acad. Dermatol., vol. 51, No. 4, pp. 500-512 (2004).
Wells, F.V. et al., Cosmetics and the Skin. New York: Reinhold Publishing Corp., 1964.
Rieger, Martin M., Ph.D. (Ed.). Harry's Cosmeticology (8thEd.), New York, NY, Chemical Publishing Co., 2000.
Phenonip(R), product brochure; Clariant UK Ltd.
Rosac(R) Cream With Sunscreen (sodium sulfacetamide 10% and sulfur 5%), product insert, Stiefel Laboratories, Inc.
Dodson Shelley A.
Goldberg Joshua B.
Nath Gary M.
Stiefel Laboratories, Inc.
The Nath Law Group
LandOfFree
Sulfacetamide formulations for treatment of rosacea does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfacetamide formulations for treatment of rosacea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfacetamide formulations for treatment of rosacea will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2759189